Bristol Myers Squibb (BMY) Q1 2025 10-Q Quarterly Report
Bristol Myers Squibb (BMY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 24, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Bristol Myers Squibb Q1 2025 10-Q Analysis
Risk Factors
- • No new or materially updated risk factors disclosed in the section, risk profile consistent with 10-K
- • Regulatory risk from reliance on FDA and EC approvals for key products like Opdivo + Yervoy expansions in HCC and CRC in 2025
Bristol Myers Squibb Q1 2025 Quarterly FinancialsXBRL
Revenue
$11.2B
▼ -5.6% YoY
Net Income
$2.5B
▲ +120.6% YoY
Net Margin
21.9%
▲ +12231bp YoY
Source: XBRL data from Bristol Myers Squibb Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Bristol Myers Squibb Quarterly Reports
Get deeper insights on Bristol Myers Squibb
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.